SCHEDULE: Ayrton Capital, Alto Fund Disclose 9.99% Stake in Apimeds

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Apimeds Pharmaceuticals US, Inc. through convertible notes.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons beneficially own 1,397,021 shares of common stock of Apimeds Pharmaceuticals US, Inc.
• This ownership represents 9.99% of the issuer's common stock.
• The shares are issuable upon the conversion of certain convertible notes held by the Reporting Persons.
• The convertible notes are subject to a 9.99% beneficial ownership blocker, preventing ownership from exceeding this threshold upon conversion.
• The percentage of class is calculated based on 12,575,983 shares outstanding as of November 12, 2025, plus the 1,397,021 shares issuable to the Reporting Persons.
• The ownership stake was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a standard disclosure of a passive ownership stake and does not inherently convey positive or negative sentiment about the issuer's performance or prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or the Reporting Persons' investment strategy beyond the current ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors who acquire more than 5% of a company's stock. This filing indicates a significant, but non-controlling, investment in Apimeds Pharmaceuticals US, Inc. by institutional and individual investors, suggesting a belief in the company's long-term value without an intent to influence management or control.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional and individual stake may be viewed positively as a vote of confidence, but the passive nature of the investment suggests no immediate impact on corporate strategy or control.
• Company Management: Awareness of a significant passive investor holding convertible notes, but no direct impact on day-to-day operations or strategic decisions is indicated.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive ownership stake and does not provide new information that would fundamentally alter the investment thesis for Apimeds Pharmaceuticals US, Inc. While a significant stake by institutional investors can be seen as a positive signal, the filing itself does not contain operational or financial updates to warrant a change from a 'hold' position for a seasoned investor. The 9.99% beneficial ownership blocker indicates a passive intent, limiting any immediate influence on the company's direction.

Keywords

Apimeds Pharmaceuticals, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, Beneficial Ownership, Convertible Notes, Pharmaceuticals, Investment Management, Equity Stake